Aberrant vascular architecture in tumors and its importance in drug-based therapies.
about
Iron oxide nanoparticles induce human microvascular endothelial cell permeability through reactive oxygen species production and microtubule remodelingQuantitative evaluation and modeling of two-dimensional neovascular network complexity: the surface fractal dimensionOverview of Methods for Overcoming Hindrance to Drug Delivery to Tumors, with Special Attention to Tumor Interstitial FluidThrombospondin 1 and vasoactive agents indirectly alter tumor blood flow.Fluid forces control endothelial sprouting.Imaging tumor hypoxia by magnetic resonance methods.Neem leaf glycoprotein prophylaxis transduces immune dependent stop signal for tumor angiogenic switch within tumor microenvironment.Methylselenocysteine: a promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugsUtilization of monoclonal antibody-targeted nanomaterials in the treatment of cancer.Targeting tumor perfusion and oxygenation to improve the outcome of anticancer therapy.Antiangiogenic therapy in human gastrointestinal malignancies.Immune cell migration as a means to control immune privilege: lessons from the CNS and tumors.Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry.Critical issues in site-specific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drug.Anastomosis of endothelial sprouts forms new vessels in a tissue analogue of angiogenesis.Antiangiogenic strategies in medulloblastoma: reality or mystery.Breast cancer cell-derived matrix supports vascular morphogenesis.Intravital imaging of CD8+ T cell function in cancer.Implantable tissue isolation chambers for analyzing tumor dynamics in vivoMetallic nanoparticles: technology overview & drug delivery applications in oncology.MR molecular imaging of tumor vasculature and vascular targets.Targeting tumor hypoxia in nasopharyngeal carcinoma.Particulate systems for targeting of macrophages: basic and therapeutic concepts.Local expression of complement factor I in breast cancer cells correlates with poor survival and recurrence.Response-Derived Input Function Estimation for Dynamic Contrast-Enhanced MRI Demonstrated by Anti-DLL4 Treatment in a Murine U87 Xenograft Model.Tumor Microenvironment on a Chip: The Progress and Future Perspective.Mathematical modeling predicts synergistic antitumor effects of combining a macrophage-based, hypoxia-targeted gene therapy with chemotherapy.Automating tumor classification with pixel-by-pixel contrast-enhanced ultrasound perfusion kinetics.Nanostructured Lipid Carrier Co-loaded with Doxorubicin and Docosahexaenoic Acid as a Theranostic Agent: Evaluation of Biodistribution and Antitumor Activity in Experimental Model.Cancer metabolism gets physical.Preoperative Ultrasonographic Evaluation for Malignancy of Soft-Tissue Sarcoma: A Retrospective Study.
P2860
Q23919175-C1F38E3D-9483-4B1C-B9AD-FF97AEA10455Q24807061-796B7347-DA15-4DFF-A6CC-EC1BF55D9AACQ26799981-AFBF53DA-5B39-4988-99F4-6B54F5CF8028Q30482804-7A9BB685-35FB-4320-8728-83BA75EBC22DQ30504415-464E3819-5ABB-4255-9DC5-F9A7D954A501Q33801254-E4C3713E-B888-4B18-A12C-265CB63E1B14Q34497392-A28CFA25-3429-4665-8EC4-43A618F43CE9Q35034404-C28E3F8C-C5AB-4B70-A41D-D26E8E9E2E29Q35578037-2893157B-3D05-4F53-B68A-729F68E007E0Q35975832-1F517405-1631-47B5-AC34-512964DE6F1DQ36591067-0F92538F-8BCD-4B69-AC7A-2A5648A5B8E0Q36593767-E9E4946A-5A57-4861-B723-6FFEABD2FD56Q36690711-C0583F97-1622-4BAC-9E3E-4D9168188E24Q37076372-549F6104-D4B2-4083-9032-FFCA7BAEB97EQ37137666-EFBD9039-11DA-46B9-80DB-F1167287D723Q37143958-A0F6FBBF-63AA-45FF-87AC-CAC7786E98D2Q37175709-59C67DC3-9C07-45B9-8CC2-29D51777D375Q37229840-F365E4D8-343C-41B6-AB9C-FC7062BC0980Q37502334-417F2353-F9C9-47F4-867C-CF7094E4F330Q37774342-51F71908-1936-48CA-9567-96AF57330F77Q37784288-584B962D-5E12-45F0-87B2-0CE8B8CD5185Q37959387-339B4805-A17F-476D-B689-A445E5902146Q38020769-9F91E976-3D26-4C08-9938-67D12A76C660Q38916801-86E0E804-B0B5-49C1-9C53-59AECE87FBB7Q38925774-08E30337-7090-4B82-8808-72BB2F582576Q41670199-50031A25-BFAB-431E-B277-71C95FEF39C8Q42121256-16EEAA1C-DEF7-428A-8647-71B946CAAC12Q42530618-0B6AD02E-51EA-4C8A-BB8B-C6BDF79E163AQ46209091-EBA4FD09-DD86-4A71-B3D7-D2F0A7D07644Q55021535-E3AF3D29-16A6-4837-8C60-A3BEDD98127CQ55287028-4F8F9649-D1D2-479D-A952-30193617623D
P2860
Aberrant vascular architecture in tumors and its importance in drug-based therapies.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Aberrant vascular architecture in tumors and its importance in drug-based therapies.
@ast
Aberrant vascular architecture in tumors and its importance in drug-based therapies.
@en
type
label
Aberrant vascular architecture in tumors and its importance in drug-based therapies.
@ast
Aberrant vascular architecture in tumors and its importance in drug-based therapies.
@en
prefLabel
Aberrant vascular architecture in tumors and its importance in drug-based therapies.
@ast
Aberrant vascular architecture in tumors and its importance in drug-based therapies.
@en
P1433
P1476
Aberrant vascular architecture in tumors and its importance in drug-based therapies.
@en
P2093
Lance L Munn
P304
P356
10.1016/S1359-6446(03)02686-2
P577
2003-05-01T00:00:00Z